Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. (Q43081790)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 April 2010

Language	Label	Description	Also known as
English	Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.	scientific article published on 28 April 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

0 references

author name string

R Goodwin

1

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

K Ding

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

L Seymour

3

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

A LeMaître

4

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

A Arnold

5

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

F A Shepherd

6

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

M Dediu

7

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

T Ciuleanu

8

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

D Fenton

9

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

M Zukin

10

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

D Walde

11

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

F Laberge

12

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

M Vincent

13

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

P M Ellis

14

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

S A Laurie

15

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

NCIC Clinical Trials Group, Kingston, Ontario, Canada

16

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

publication date

28 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

2220-2226

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Angiogenic growth factors and hypertension

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Quantifying hypertension in patients with cancer treated with sorafenib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Home blood-pressure monitoring in patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ221

21 January 2018

Identifiers

10.1093/ANNONC/MDQ221

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43081790&oldid=1592297135"